10x Genomics Inc. Business Model Research Guide
Direct answer: This business model research guide covers how to verify 10x Genomics Inc.'s revenue model, customer economics, cost structure, and competitive advantages from primary SEC filings. Use each section as a research checklist rather than a finished analysis. Every claim must be traced to a current 10-K, 10-Q, or 8-K before reaching a conclusion.
What Do the Reported Numbers Say About the 10x Genomics Inc. Business Model?
10x Genomics Inc. has not broken its revenue out by segment, product or region in a way Swoopr can read from its filings, so this table shows the economics of the whole business: what it earned, what it kept and what it spent on equipment, for the fiscal years ended December 31, 2022 to December 31, 2025.
| Fiscal year | Revenue | Growth | Operating margin | Net margin | Capital spending share of revenue | Free cash flow margin |
|---|---|---|---|---|---|---|
| FY2022 | $516 million | n/a | -32.5% | -32.1% | 25.5% | -32.0% |
| FY2023 | $619 million | +19.8% | -42.9% | -41.2% | 7.9% | -10.3% |
| FY2024 | $611 million | -1.3% | -31.9% | -29.9% | 2.0% | -0.9% |
| FY2025 | $643 million | +5.2% | -9.5% | -6.8% | 0.9% | 20.2% |
In fiscal 2025, capital spending was 0.9% of revenue.
"Not reported" means the company filed no value under the standard tag, not that the amount was zero. Source: SEC EDGAR: 10x Genomics, Inc. Form 10-K filed February 13, 2026.
Revenue model
For 10x Genomics Inc., the revenue model review should cover manufacturing, aerospace, transportation, construction, engineering or industrial services.
Customer economics
For 10x Genomics Inc., the customer economics review should cover who pays, why they pay, contract or transaction structure, concentration and switching behavior.
Cost structure
For 10x Genomics Inc., the cost structure review should cover Industrial businesses often combine meaningful fixed costs with long product cycles and working-capital swings. Backlog quality, price-cost discipline, installed-base service revenue and capacity utilization frequently matter more than headline revenue growth alone..
Scale and competitive advantage
For 10x Genomics Inc., the scale and competitive advantage review should cover distribution, installed base, data, regulation, brand, network effects or cost position where supported.
Capital intensity
For 10x Genomics Inc., the capital intensity review should cover working capital, capex, acquisitions and other reinvestment required to sustain growth.
Research Checklist
- Orders: For 10x Genomics Inc. (TXG), determine from current primary sources whether orders is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Backlog: For 10x Genomics Inc. (TXG), determine from current primary sources whether backlog is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Shipments: For 10x Genomics Inc. (TXG), determine from current primary sources whether shipments is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Price Realization: For 10x Genomics Inc. (TXG), determine from current primary sources whether price realization is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Capacity Utilization: For 10x Genomics Inc. (TXG), determine from current primary sources whether capacity utilization is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Aftermarket Demand: For 10x Genomics Inc. (TXG), determine from current primary sources whether aftermarket demand is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Project Execution: For 10x Genomics Inc. (TXG), determine from current primary sources whether project execution is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Manufacturers: For 10x Genomics Inc. (TXG), determine from current primary sources whether manufacturers is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Governments: For 10x Genomics Inc. (TXG), determine from current primary sources whether governments is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Transport Operators: For 10x Genomics Inc. (TXG), determine from current primary sources whether transport operators is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
Related Research
Source Standard
The latest annual report, quarterly filings, material 8-Ks and official investor-relations disclosures are the primary sources. Do not infer company-specific figures from the sector framework.
References
Company financial disclosures, SEC filings and investor-relations materials are the authoritative sources for financial figures cited on this page. Individual company SEC filings are available at SEC EDGAR.